MoonLake Immunotherapeutics’s Price-to-Sales Ratio at a glance
MoonLake Immunotherapeutics reports price-to-sales ratio of 0x for Dec 2024. The prior period recorded 0x (Dec 2023). Year over year the metric moved +0. The rolling three-period average stands at 0x. Data last refreshed Dec 7, 2025, 1:33 AM.
Latest reading
0x · Dec 2024
YoY movement
+0
Rolling average
0x
Current Price-to-Sales Ratio
0x
+0
–
Rolling average
0x
Latest Value
0x
Dec 2024
YoY Change
+0
Absolute
YoY Change %
–
Rate of change
3-Period Avg
0x
Smoothed
Narrative signal
MoonLake Immunotherapeutics’s price-to-sales ratio stands at 0x for Dec 2024. Year-over-year, the metric shifted by +0, translating into a – rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How price-to-sales ratio shapes MoonLake Immunotherapeutics's story
As of Dec 2024, MoonLake Immunotherapeutics reports price-to-sales ratio of 0x. Track price-to-sales multiples to contextualize revenue-driven valuation swings and peer comparisons.
When to use price-to-sales
P/S is helpful for companies with slim or volatile profits. It shows how rich investors value each dollar of revenue.
Compare against industry norms
High-growth software firms command higher P/S ratios than retailers. Stack the metric versus sector averages to read sentiment.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
MoonLake Immunotherapeutics (MLTX) FAQs
Answers tailored to MoonLake Immunotherapeutics’s price-to-sales ratio profile using the latest Financial Modeling Prep data.
What is MoonLake Immunotherapeutics's current price-to-sales ratio?
As of Dec 2024, MoonLake Immunotherapeutics reports price-to-sales ratio of 0x. This reading reflects the latest filings and price data for MLTX.
How is MoonLake Immunotherapeutics's price-to-sales ratio trending year over year?
Year-over-year, the figure shifts by +0. Pair this context with revenue growth and free cash flow signals to gauge momentum for MLTX.
Why does price-to-sales ratio matter for MoonLake Immunotherapeutics?
Price-to-sales compares market capitalization with revenue to assess valuation against top-line performance. For MoonLake Immunotherapeutics, operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is MoonLake Immunotherapeutics's price-to-sales ratio above its recent average?
MoonLake Immunotherapeutics's rolling three-period average sits at 0x. Comparing the latest reading of 0x to that baseline highlights whether momentum is building or fading for MLTX.
How frequently is MoonLake Immunotherapeutics's price-to-sales ratio refreshed?
Data for MLTX was last refreshed on Dec 7, 2025, 1:33 AM and updates automatically every 24 hours, keeping your valuation inputs current.